346 related articles for article (PubMed ID: 12948013)
41. Effects of capsaicin on cellular damage and monolayer permeability in human intestinal Caco-2 cells.
Tsukura Y; Mori M; Hirotani Y; Ikeda K; Amano F; Kato R; Ijiri Y; Tanaka K
Biol Pharm Bull; 2007 Oct; 30(10):1982-6. PubMed ID: 17917278
[TBL] [Abstract][Full Text] [Related]
42. Possible involvement of multiple P-glycoprotein-mediated efflux systems in the transport of verapamil and other organic cations across rat intestine.
Saitoh H; Aungst BJ
Pharm Res; 1995 Sep; 12(9):1304-10. PubMed ID: 8570526
[TBL] [Abstract][Full Text] [Related]
43. Montmorillonite-surfactant hybrid particles for modulating intestinal P-glycoprotein-mediated transport.
Nielsen RB; Kahnt A; Dillen L; Wuyts K; Snoeys J; Nielsen UG; Holm R; Nielsen CU
Int J Pharm; 2019 Nov; 571():118696. PubMed ID: 31525443
[TBL] [Abstract][Full Text] [Related]
44. Permeability dominates in vivo intestinal absorption of P-gp substrate with high solubility and high permeability.
Cao X; Yu LX; Barbaciru C; Landowski CP; Shin HC; Gibbs S; Miller HA; Amidon GL; Sun D
Mol Pharm; 2005; 2(4):329-40. PubMed ID: 16053336
[TBL] [Abstract][Full Text] [Related]
45. P-glycoprotein is responsible for the poor intestinal absorption and low toxicity of oral aconitine: in vitro, in situ, in vivo and in silico studies.
Yang C; Zhang T; Li Z; Xu L; Liu F; Ruan J; Liu K; Zhang Z
Toxicol Appl Pharmacol; 2013 Dec; 273(3):561-8. PubMed ID: 24120885
[TBL] [Abstract][Full Text] [Related]
46. Differences in the absorption, metabolism and biliary excretion of a diastereomeric pair of alphavbeta3-antagonists in rat: limited role of P-glycoprotein.
Prueksaritanont T; Meng Y; Ma B; Leppert P; Hochman J; Tang C; Perkins J; Zrada M; Meissner R; Duggan ME; Lin JH
Xenobiotica; 2002 Mar; 32(3):207-20. PubMed ID: 11958560
[TBL] [Abstract][Full Text] [Related]
47. Multiple efflux pumps are involved in the transepithelial transport of colchicine: combined effect of p-glycoprotein and multidrug resistance-associated protein 2 leads to decreased intestinal absorption throughout the entire small intestine.
Dahan A; Sabit H; Amidon GL
Drug Metab Dispos; 2009 Oct; 37(10):2028-36. PubMed ID: 19589874
[TBL] [Abstract][Full Text] [Related]
48. Region-dependent modulation of intestinal permeability by drug efflux transporters: in vitro studies in mdr1a(-/-) mouse intestine.
Stephens RH; Tanianis-Hughes J; Higgs NB; Humphrey M; Warhurst G
J Pharmacol Exp Ther; 2002 Dec; 303(3):1095-101. PubMed ID: 12438532
[TBL] [Abstract][Full Text] [Related]
49. Improvement of intestinal absorption of P-glycoprotein substrate by D-tartaric acid.
Iida A; Tomita M; Idota Y; Takizawa Y; Hayashi M
Drug Metab Pharmacokinet; 2006 Oct; 21(5):424-8. PubMed ID: 17072096
[TBL] [Abstract][Full Text] [Related]
50. Effect of P-glycoprotein expression levels on the concentration-dependent permeability of drugs to the cell membrane.
Shirasaka Y; Sakane T; Yamashita S
J Pharm Sci; 2008 Jan; 97(1):553-65. PubMed ID: 17828734
[TBL] [Abstract][Full Text] [Related]
51. P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir.
Huisman MT; Smit JW; Wiltshire HR; Hoetelmans RM; Beijnen JH; Schinkel AH
Mol Pharmacol; 2001 Apr; 59(4):806-13. PubMed ID: 11259625
[TBL] [Abstract][Full Text] [Related]
52. A kinetic evaluation of the absorption, efflux, and metabolism of verapamil in the autoperfused rat jejunum.
Johnson BM; Chen W; Borchardt RT; Charman WN; Porter CJ
J Pharmacol Exp Ther; 2003 Apr; 305(1):151-8. PubMed ID: 12649363
[TBL] [Abstract][Full Text] [Related]
53. Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs.
Patel J; Mitra AK
Pharmacogenomics; 2001 Nov; 2(4):401-15. PubMed ID: 11722289
[TBL] [Abstract][Full Text] [Related]
54. Application of compartmental modeling to an examination of in vitro intestinal permeability data: assessing the impact of tissue uptake, P-glycoprotein, and CYP3A.
Johnson BM; Charman WN; Porter CJ
Drug Metab Dispos; 2003 Sep; 31(9):1151-60. PubMed ID: 12920171
[TBL] [Abstract][Full Text] [Related]
55. The role of P-glycoprotein in intestinal transport versus the BBB transport of tetraphenylphosphonium.
Swed A; Eyal S; Madar I; Zohar-Kontante H; Weiss L; Hoffman A
Mol Pharm; 2009; 6(6):1883-90. PubMed ID: 19722701
[TBL] [Abstract][Full Text] [Related]
56. Screening of multidrug-resistance sensitive drugs by in situ brain perfusion in P-glycoprotein-deficient mice.
Cisternino S; Rousselle C; Dagenais C; Scherrmann JM
Pharm Res; 2001 Feb; 18(2):183-90. PubMed ID: 11405289
[TBL] [Abstract][Full Text] [Related]
57. Prediction of in vivo intestinal absorption enhancement on P-glycoprotein inhibition, from rat in situ permeability.
Varma MV; Panchagnula R
J Pharm Sci; 2005 Aug; 94(8):1694-704. PubMed ID: 15986467
[TBL] [Abstract][Full Text] [Related]
58. Factors and dosage formulations affecting the solubility and bioavailability of P-glycoprotein substrate drugs.
Murakami T; Bodor E; Bodor N
Expert Opin Drug Metab Toxicol; 2021 May; 17(5):555-580. PubMed ID: 33703995
[No Abstract] [Full Text] [Related]
59. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
Hendrikx JJ; Lagas JS; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
Int J Cancer; 2013 May; 132(10):2439-47. PubMed ID: 23090875
[TBL] [Abstract][Full Text] [Related]
60. Role of P-glycoprotein in intestinal absorption of FB2, a promising Abl/Src dual tyrosine kinase inhibitor.
Huang K; Hu J; Li X; Li Y
Drug Metab Pharmacokinet; 2012; 27(5):486-94. PubMed ID: 22447116
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]